Alvotech announces marketing approval in Japan for three biosimilars

Alvotech (ALVO) announced that its commercialization partner in Japan, Fuji Pharma, has received marketing approval for three new biosimilars from the Japanese Ministry of Health, Labor and Welfare. The biosimilars approved for the Japanese market are AVT03, a biosimilar to Ranmark, AVT05, a biosimilar to Simponi and AVT06, a biosimilar to Eylea. Based on publicly available information, AVT05 is the first golimumab biosimilar to be approved for sale in major markets globally.